+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 70Years
All Genders
ID07598708

Randomized Study Comparing Cleminorexton and Placebo for Treating Narcolepsy Type 1 and Type 2

Led by Centessa Pharmaceuticals (UK) Limited · Updated on 2026-11-03

222

Participants Needed

26

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety, tolerability, and effects of cleminorexton, a drug designed to mimic orexin, in people with Narcolepsy Type 1 NT1 and Narcolepsy Type 2 NT2, which cause excessive daytime sleepiness. It studies how cleminorexton impacts symptoms like sleepiness and cataplexy, a sudden loss of muscle strength seen in NT1, to learn more about its effects on these rare sleep disorders. Participants will be randomly assigned to one of several groups receiving either two different doses of cleminorexton or a matching placebo. The study includes separate groups for NT1 and NT2. Treatment consists of oral capsules taken during the trial, which lasts for 12 weeks. The study may expand in the future to include participants with idiopathic hypersomnia under a protocol amendment. During the study, participants will undergo regular assessments including sleep latency tests, sleepiness scales, cataplexy rate tracking, and other narcolepsy severity measures. Safety will be monitored through laboratory tests, vital signs, ECGs, and suicide risk assessments. Pharmacokinetic measurements of the drug will also be collected. The total participation duration includes baseline and 12-week treatment evaluations.

CONDITIONS

Brief Title

A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence

Research Team

C

Centessa Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here